Clinical research has reported that MR1 expression in tumors varies significantly, with some cancers upregulating MR1 as a potential immune evasion strategy, correlating with poor prognosis (72), while others exhibit reduced MR1 expression, potentially limiting MAIT and diverse MR1T cell activation (26, 82). Here, MR1 is linked to cancer.